Hospitalisations related to benzodiazepine, Z-drug, and opioid treatment in Italy: a claim on the risks associated with inappropriate use

Author:

Mattioli Irene,Bettiol Alessandra,Crescioli GiadaORCID,Bonaiuti Roberto,Prisco Domenico,Mannaioni Guido,Lombardi Niccolò,Vannacci Alfredo,

Abstract

Abstract Purpose Benzodiazepines (BZD), Z-drugs (ZD), and opioids share a high risk of abuse. This study assessed and characterised adverse events (AEs) related to BDZ, ZD, and opioids leading to emergency department (ED) visits in the Italian setting. Methods ED accesses related to BDZ, ZD, and/or opioids were analysed from the MEREAFaPS database. Information on AEs, suspected and concomitant medications was retrieved. Multivariate logistic regression was used to estimate the reporting odds ratios (RORs) of hospitalisation according to the different treatments. Results A total of 5,970 pharmacovigilance reports involving BZD/ZD (n = 3,106), opioids (n = 2,767), or their combination (n = 97) were analysed. Compared to opioids, patients with BZD/ZD-related AEs were often younger (51 vs 64 years), more frequently presented 2+ suspected medications (13 vs 3%), and often had a history of abuse (4%). Twenty-three percent of BZD/ZD-related AEs were related to drug abuse (vs 2% of opioid-related ones) and frequently required patient hospitalisation (52% vs 24%), despite the significantly lower clinical complexity of these patients as compared to those on opioids. An increased risk of hospitalisation was found for flurazepam (ROR 1.62; 95% CI, 1.18–2.22), prazepam (2.66; 1.05–6.70), lorazepam (1.26; 1.07–1.49), and morphine (1.76; 1.11–2.79). Conclusions These results indicate that, in Italy, the inappropriate use of BZD/ZD is a relevant heath issue, often leading to serious AEs requiring patients’ ED visits and hospitalisation, especially in young women and patients with a history of substance abuse.

Funder

Agenzia Italiana del Farmaco, Ministero della Salute

Università degli Studi di Firenze

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Reference32 articles.

1. Lyden J, Binswanger IA (2019) The United States opioid epidemic. Semin Perinatol 43(3):123–131. https://doi.org/10.1053/j.semperi.2019.01.001

2. INCB Narcotic Drugs Stupéfiants Estupefacientes (2020) Available online at: https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2020/Narcotic_Drugs_Technical_publication_2020.pdf. Accessed 2 Mar 2022

3. UNODC World Drug Report (2019) Available online at: https://wdr.unodc.org/wdr2019/prelaunch/pre-launchpresentation_WDR_2019.pdf. Accessed 2 Mar 2022

4. Califf RM, Woodcock J, Ostroff S (2016) A proactive response to prescription opioid abuse. N Engl J Med 374(15):1480–1485. https://doi.org/10.1056/NEJMsr1601307

5. Mercadante S (2019) Potential strategies to combat the opioid crisis. Expert Opin Drug Saf 18(3):211–217. https://doi.org/10.1080/14740338.2019.1579796

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3